Amyotrophic Lateral Sclerosis: A Focus on Disease Progression

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Calvo, Ana C ^a   Manzano, Raquel ^a   Mendonça, Deise M F ^b   Muñoz, María J ^a   Zaragoza, Pilar ^a   Osta, Rosario ^a  

^a UNIVERSITY OF ZARAGOZA   (Spain)

^b FEDERAL UNIVERSITY OF SERGIPE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL FEATURE; DISEASE COURSE; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANIMAL; METABOLISM; PATHOLOGY;

ANIMALIA;

BIOLOGICAL MARKER;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 84920553828     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/925101     Document Type: Review

References (84)

1. B. R. Brooks, R. G. Miller, M. Swash, and T. L. Munsat, "El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis," Amyotrophic Lateral Sclerosis, vol. 1, no. 5, pp. 293-299, 2000.
2. C. Lomen-Hoerth, J. Murphy, S. Langmore, J.H. Kramer, R. K. Olney, and B. Miller, "Are amyotrophic lateral sclerosis patients cognitively normal? Neurology, vol. 60, no. 7, pp. 1094-1097, 2003.
3. R. Rusina, P. Ridzon, P. Kulisták et al., "Relationship between ALS and the degree of cognitive impairment, markers of neurodegeneration and predictors for poor outcome. A prospective study," European Journal of Neurology, vol. 17, no. 1, pp. 23-30, 2010.
4. G. M. Ringholz, S.H. Appel,M. Bradshaw, N. A. Cooke, D. M. Mosnik, and P. E. Schulz, "Prevalence and patterns of cognitive impairment in sporadic ALS," Neurology, vol. 65,no. 4, pp. 586-590, 2005.
5. A. P. Hays, A. Roxas, S. A. Sadia et al., "A monoclonal IgA in patient with amyotrophic lateral sclerosis reacts with neurofilaments and surface antigen on neuroblastoma cells," Journal of Neuropathology and Experimental Neurology, vol. 49, no. 4, pp. 383-398, 1990.
6. L.C. Wijesekera and P.N. Leigh, "Amyotrophic lateral sclerosis," Orphanet Journal of Rare Diseases, vol. 4, no. 1, article 3, 2009.
7. M. Katsuno, F. Tanaka, and G. Sobue, "Perspectives onmolecular targeted therapies and clinical trials for neurodegenerative diseases," Journal of Neurology, Neurosurgery and Psychiatry, vol. 83, no. 3, pp. 329-335, 2012.
8. A. R. Jones, I. Woollacott, A. Shatunov et al., "Residual association at C9orf72 suggests an alternative amyotrophic lateral sclerosis-causing hexanucleotide repeat," Neurobiology of Aging, vol. 34, no. 9, pp. 2234.e1-2234.e7, 2013.
9. A. Chiò, S. Battistini, A. Calvo et al., "Genetic counselling in ALS: Facts, uncertainties and clinical suggestions," Journal of Neurology, Neurosurgery and Psychiatry, vol. 85, no. 5, pp. 478-485, 2014.
10. D. R. Rosen, T. Siddique, D. Patterson et al., "Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis," Nature, vol. 362, no. 6415, pp. 59-62, 1993.
11. P. Pasinelli and R. H. Brown, "Molecular biology of amyotrophic lateral sclerosis: Insights from genetics," Nature Reviews Neuroscience, vol. 7, no. 9, pp. 710-723, 2006.
12. X.W. Su, J. R. Broach, J. R. Connor et al., "Genetic heterogeneity of ALS: Implications for clinical practice and research," Muscle & Nerve, vol. 49, no. 6, pp. 786-803, 2014.
13. S. Cluskey and D. B. Ramsden, "Mechanisms of neurodegeneration in amyotrophic lateral sclerosis,"Molecular Pathology, vol. 54, no. 6, pp. 386-392, 2001.
14. J. C. Schymick, K. Talbot, and B. J. Traynor, "Genetics of sporadic amyotrophic lateral sclerosis," Human Molecular Genetics, vol. 16, no. 2, pp. R233-R242, 2007.
15. D. J. Graber, W. F. Hickey, and B. T. Harris, "Progressive changes in microglia and macrophages in spinal cord and peripheral nerve in the transgenic rat model of amyotrophic lateral sclerosis," Journal of Neuroinflammation, vol. 7, article 8, 2010.
16. S. Vucic and M. C. Kiernan, "Pathophysiology of neurodegeneration in familial amyotrophic lateral sclerosis," Current Molecular Medicine, vol. 9, no. 3, pp. 255-272, 2009.
17. A. M. Chancellor, J. M. Slattery, H. Fraser, R. J. Swingler, S. M. Holloway, and C. P. Warlow, "The prognosis of adult-onset motor neuron disease: A prospective study based on the Scottish motor neuron disease register," Journal of Neurology, vol. 240, no. 6, pp. 339-346, 1993.
18. J.-M. Burgunder, L. Schöls, J. Baets et al., "EFNS guidelines for the molecular diagnosis of neurogenetic disorders: Motoneuron, peripheral nerve and muscle disorders," European Journal of Neurology, vol. 18, no. 2, pp. 207-217, 2011.
19. C.A. Johnston, B. R. Stanton, M. R. Turner et al., "Amyotrophic lateral sclerosis in an urban setting: A population based study of inner city London," Journal of Neurology, vol. 253, no. 12, pp. 1642-1643, 2006.
20. R. Bowser and D. Lacomis, "Applying proteomics to the diagnosis and treatment of ALS and related diseases," Muscle and Nerve, vol. 40, no. 5, pp. 753-762, 2009.
21. C. Lomen-Hoerth, "Amyotrophic lateral sclerosis from bench to bedside," Seminars in Neurology, vol. 28, no. 2, pp. 205-211, 2008.
22. S. M. Khader and F. G. Greiner, "Neuroradiology case of the day," Radiographics, vol. 19, no. 6, pp. 1696-1698, 1999.
23. S. C. Bondy and D. K. Lee, "Oxidative stress induced by glutamate receptor agonists," Brain Research, vol. 610, no. 2, pp. 229-233, 1993.
24. F. M. Menzies, M. R. Cookson, R. W. Taylor et al., "Mitochondrial dysfunction in a cell culturemodel of familial amyotrophic lateral sclerosis," Brain, vol. 125, no. 7, pp. 1522-1533, 2002.
25. S. Vucic, J. Howells, L. Trevillion, and M. C. Kiernan, "Assessment of cortical excitability using threshold tracking techniques," Muscle and Nerve, vol. 33, no. 4, pp. 477-486, 2006.
26. S. Vucic, G. A. Nicholson, and M. C. Kiernan, "Cortical hyper excitability may precede the onset of familial amyotrophic lateral sclerosis," Brain, vol. 131, no. 6, pp. 1540-1550, 2008.
27. M. de Carvalho, R. Dengler, A. Eisen et al., "Electrodiagnostic criteria for diagnosis of ALS," Clinical Neurophysiology, vol. 119, no. 3, pp. 497-503, 2008.
28. A. A. Makki and M. Benatar, "The electromyographic diagnosis of amyotrophic lateral sclerosis: Does the evidence support the El Escorial criteria? Muscle and Nerve, vol. 35, no. 5, pp. 614-619, 2007.
29. J. Costa, S. Swash, and M. de Carvalho, "Awaji criteria for the diagnosis of Amyotrophic Lateral Sclerosis: A systematic review," Archives of Neurology, vol. 69,no. 11,pp. 1410-1416, 2012.
30. A. C. Pinto, M. Alves, A. Nogueira et al., "Can amyotrophic lateral sclerosis patients with respiratory insufficiency exercise? Journal of the Neurological Sciences, vol. 169, no. 1-2, pp. 69-75, 1999.
31. A. Chiò, A. Calvo, A. Ilardi et al., "Lower serum lipid levels are related to respiratory impairment in patients with ALS," Neurology, vol. 73, no. 20, pp. 1681-1685, 2009.
32. F. Azuaje, Bioinformatics and Biomarker Discovery: Omic Data Analysis for Personalized Medicine,Wiley-Blackwell,West Sussex, UK, 2010.
33. R. Balendra, A. Jones, N. Jivraj et al., "Estimating clinical stage of amyotrophic lateral sclerosis from the ALS Functional Rating Scale," Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, vol. 15, no. 3-4, pp. 279-284, 2014.
34. A. Chiò, E. R. Hammond, G. Mora et al., "Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis," Journal ofNeurology,Neurosurgery&Psychiatry, 2013.
35. M.-M. El Mendili, J. Cohen-Adad, M. Pelegrini-Issac et al., "Multi-parametric spinal cord MRI as potential progression marker in amyotrophic lateral sclerosis," PLoS ONE, vol. 9, no. 4, Article ID e95516, 2014.
36. L. Dupuis, J.-L. Gonzalez de Aguilar, F. di Scala et al., "Nogo provides a molecular marker for diagnosis of amyotrophic lateral sclerosis," Neurobiology of Disease, vol. 10, no. 3, pp. 358-365, 2002.
37. A. Fergani, L. Dupuis, N. Jokic et al., "Reticulons as markers of neurological diseases: Focus on amyotrophic lateral sclerosis," Neurodegenerative Diseases, vol. 2, no. 3-4, pp. 185-194, 2005.
38. T. Karnezis,W. Mandemakers, J. L. McQualter et al., "Reticulons as markers of neurological diseases: Focus on amyotrophic lateral sclerosis," Nature Neuroscience, vol. 7, no. 7, pp. 736-744, 2004.
39. N. Jokic, J. Gonzalez De Aguilar, P. Pradat et al., "Nogo expression in muscle correlates with amyotrophic lateral sclerosis severity," Annals of Neurology, vol. 57, no. 4, pp. 553-556, 2005.
40. Z. Zhao, D. J. Lange, L. Ho et al., "Vgf is a novel biomarker associated with muscle weakness in amyotrophic lateral sclerosis (ALS), with a potential role in disease pathogenesis," International Journal of Medical Sciences, vol. 5, no. 2, pp. 92-99, 2008.
41. A.F. Keller,M. Gravel, and J. Kriz, "Live imagingof amyotrophic lateral sclerosis pathogenesis: Disease onset is characterized by marked induction of GFAP in schwann cells," GLIA, vol. 57, no. 10, pp. 1130-1142, 2009.
42. X. Zhang, S. Chen, L. Li, Q. Wang, and W. Le, "Decreased level of 5-methyltetrahydrofolate: A potential biomarker for pre-symptomatic amyotrophic lateral sclerosis," Journal of the Neurological Sciences, vol. 293, no. 1-2, pp. 102-105, 2010.
43. T. Philips, L. de Muynck, H. N. T. Thu et al., "Microglial upregulation of progranulin as a marker of motor neuron degeneration," Journal of Neuropathology and Experimental Neurology, vol. 69, no. 12, pp. 1191-1200, 2010.
44. Y.N. Gerber, J. Sabourin,M. Rabano, M. D. M. Vivanco, and F. E. Perrin, "Early functional deficit and microglial disturbances in a mouse model of amyotrophic lateral sclerosis," PLoS ONE, vol. 7, no. 4, Article ID e36000, 2012.
45. G. Almer, S. Vukosavic, N. Romero, and S. Przedborski, "Inducible nitric oxide synthase up-regulation in a transgenic mouse model of familial amyotrophic lateral sclerosis," Journal of Neurochemistry, vol. 72, no. 6, pp. 2415-2425, 1999.
46. M. C. Evans, S. Serres, and A. A. Khrapitchev, "T2-weighted MRI detects presymptomatic pathology in the SOD1 mouse model of ALS," Journal of Cerebral Blood Flow & Metabolism, vol. 34, pp. 785-793, 2014.
47. C. Nicaise, D. Mitrecic, P. Demetter et al., "Impaired bloodbrain and blood-spinal cord barriers in mutant SOD1-linked ALS rat," Brain Research, vol. 1301, pp. 152-162, 2009.
48. C. P. W. Soon, P. J. Crouch, B. J. Turner et al., "Serum matrix metalloproteinase-9 activity is dysregulated with disease progression in the mutant SOD1 transgenic mice," Neuromuscular Disorders, vol. 20, no. 4, pp. 260-266, 2010.
49. J. I?zecka, Z. Stelmasiak, and B. Dobosz, "Matrix metalloproteinase- 9 (MMP-9) activity in cerebrospinal fluid of amyotrophic lateral sclerosis patients," Neurologia i Neurochirurgia Polska, vol. 35, no. 6, pp. 1035-1043, 2001.
50. T. Shinozawa, Y. Urade, T. Maruyama, and D. Watabe, "Tetranor PGDM analyses for the amyotrophic lateral sclerosis: Positive and simple diagnosis and evaluation of drug effect," Biochemical and Biophysical Research Communications, vol. 415, no. 4, pp. 539-544, 2011.
51. K. Boylan, C. Yang, J. Crook et al., "Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF-H) in blood of ALS model rodents and ALS patients: Evaluation of blood pNF-H as a potential ALS biomarker," Journal of Neurochemistry, vol. 111, no. 5, pp. 1182-1191, 2009.
52. A. C. Calvo, R. Manzano, G. Atencia-Cibreiro et al., "Genetic biomarkers for ALS disease in transgenic SOD1 G93A mice," PLoS ONE, vol. 7, no. 3,Article ID e32632, 2012.
53. S. Ranganathan, E. Williams, P. Ganchev et al., "Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis," Journal of Neurochemistry, vol. 95,no. 5, pp. 1461-1471, 2005.
54. K. Fujita,M. Honda, R. Hayashi et al., "Transglutaminase activity in serum and cerebrospinal fluid in sporadic amyotrophic lateral sclerosis: A possible use as an indicator of extent of the motor neuron loss," Journal of the Neurological Sciences, vol. 158, no. 1, pp. 53-57, 1998.
55. K. Obayashi, K. Sato, R. Shimazaki et al., "Salivary chromogranin A: Useful and quantitative biochemical marker of affective state in patients with amyotrophic lateral sclerosis," Internal Medicine, vol. 47, no. 21, pp. 1875-1879, 2008.
56. C. Figueroa-Romero, J. Hur, D. E. Bender et al., "Identification of epigenetically altered genes in sporadic amyotrophic lateral sclerosis," PLoS ONE, vol. 7, no. 12, Article IDe52672, 2012.
57. S. Petri, M. Kiaei, M. Damiano et al., "Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis," Journal of Neurochemistry, vol. 98, no. 4, pp. 1141-1148, 2006.
58. H. S. Jin, I. C. Sung, R. L. Hyang et al., "Concurrent administration ofNeu2000 and lithium produces marked improvement of motor neuron survival, motor function, and mortality in a mouse model of amyotrophic lateral sclerosis," Molecular Pharmacology, vol. 71, no. 4, pp. 965-975, 2007.
59. M. Kiaei, K. Kipiani, S. Petri, J. Chen, N. Y. Calingasan, and M. F. Beal, "Celastrol blocks neuronal cell death and extends life in transgenic mousemodel of amyotrophic lateral sclerosis," Neurodegenerative Diseases, vol. 2, no. 5, pp. 246-254, 2006.
60. S. Petri, N. Y. Calingasan, O. A. Alsaied et al., "The lipophilic metal chelators DP-109 and DP-460 are neuroprotective in a transgenic mouse model of amyotrophic lateral sclerosis," Journal of Neurochemistry, vol. 102, no. 3, pp. 991-1000, 2007.
61. C. Benkler, D. Offen, E. Melamed et al., "Recent advances in amyotrophic lateral sclerosis research: Perspectives for personalized clinical application,"The EPMA Journal, vol. 1, no. 2, pp. 343-361, 2010.
62. P. Bigini, M. Repici, G. Cantarella et al., "Recombinant human TNF-binding protein-1 (rhTBP-1) treatment delays both symptoms progression and motor neuron loss in thewobblermouse," Neurobiology of Disease, vol. 29, no. 3, pp. 465-476, 2008.
63. J. M. Lincecum, F. G. Vieira, M. Z. Wang et al., "From transcriptome analysis to therapeutic anti-CD40L treatment in the SOD1 model of amyotrophic lateral sclerosis," Nature Genetics, vol. 42, no. 5, pp. 392-399, 2010.
64. M. Kiaei, S. Petri, K. Kipiani et al., "Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis," Journal of Neuroscience, vol. 26, no. 9, pp. 2467-2473, 2006.
65. A. D. Zurn, L. Winkel, A. Menoud et al., "Combined effects of GDNF, BDNF, and CNTF on motoneuron differentiation in vitro," Journal of Neuroscience Research, vol. 44, no. 2, pp. 133-141, 1996.
66. T. Mennini, M. de Paola, P. Bigini et al., "Nonhematopoietic erythropoietin derivatives preventmotoneuron degeneration in vitro and in vivo," Molecular Medicine, vol. 12, no. 7-8, pp. 153-160, 2006.
67. E. F. Goodall and K. E. Morrison, "Amyotrophic lateral sclerosis (motor neuron disease): Proposedmechanisms and pathways to treatment," Expert Reviews in Molecular Medicine, vol. 8, no. 11, pp. 1-22, 2006.
68. S. Kalra, A. Genge, and D. L. Arnold, "A prospective, rand omized, placebo-controlled evaluation of corticoneuronal response to intrathecal BDNF therapy in ALS using magnetic resonance spectroscopy: Feasibility and results," Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, vol. 4, no. 1, pp. 22-26, 2003.
69. J. H. Weishaupt, C. Bartels, E. Pölking et al., "Reduced oxidative damage in ALS by high-dose enteral melatonin treatment," Journal of Pineal Research, vol. 41, no. 4, pp. 313-323, 2006.
70. C. E. Le Pichon, S. L. Dominguez, H. Solanoy et al., "EGFR inhibitor erlotinib delays disease progression but does not extend survival in the SOD1 mouse model of ALS," PLoS ONE, vol. 8, no. 4, Article IDe62342, 2013.
71. M. Peviani, E. Salvaneschi, L. Bontempi et al., "Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation," Neurobiology of Disease, vol. 62, pp. 218-232, 2014.
72. A. Cifra, F. Nani, and A. Nistri, "Riluzole is a potent drug to protect neonatal rat hypoglossal motoneurons in vitro from excitotoxicity due to glutamate uptake block," European Journal of Neuroscience, vol. 33, no. 5, pp. 899-913, 2011.
73. P. H. Gordon, "Amyotrophic lateral sclerosis: An update for 2013 clinical features, pathophysiology,management and therapeutic trials," Aging and Disease, vol. 4, no. 5, pp. 295-310, 2013.
74. Y. N. Gerber, A. Privat, and F. E. Perrin, "Gacyclidine improves the survival and reduces motor deficits in a mouse model of amyotrophic lateral sclerosis," Frontiers in Cellular Neuroscience, vol. 7, p. 280, 2013.
75. M. Azzouz, G. S. Ralph, E. Storkebaum et al., "VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model," Nature, vol. 429, no. 6990, pp. 413-417, 2004.
76. B. K. Kaspar, J. Lladó,N. Sherkat, J.D. Rothstein, and F. H. Gage, "Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model," Science, vol. 301, no. 5634, pp. 839-842, 2003.
77. J. Ciriza, M. Moreno-Igoa, A. C. Calvo et al., "A genetic fusion GDNF-C fragment of tetanus toxin prolongs survival in a symptomatic mouse ALS model," Restorative Neurology and Neuroscience, vol. 26, no. 6, pp. 459-465, 2008.
78. M. Moreno-Igoa, A. C. Calvo, C. Penas et al., "Fragment C of tetanus toxin, more than a carrier. Novel perspectives in nonviral ALS gene therapy," Journal of Molecular Medicine, vol. 88, no. 3, pp. 297-308, 2010.
79. F. Locatelli, S. Corti, D. Papadimitriou et al., "Fas small interfering RNA reduces motoneuron death in amyotrophic lateral sclerosis mice," Annals of Neurology, vol. 62, no. 1, pp. 81-92, 2007.
80. S. Corti, F. Locatelli, D. Papadimitriou et al., "Neural stem cells LewisX + CXCR4 + modify disease progression in an amyotrophic lateral sclerosis model," Brain, vol. 130, no. 5, pp. 1289-1305, 2007.
81. M. Suzuki, J. McHugh, C. Tork et al., "GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection muscule, in a rat model of familial ALS," PLoS ONE, vol. 2, article e689, no. 8, 2007.
82. C. Choi, Y. Lee, H. Kim, S. H. Kim, and H. Suh-Kim, "Neural induction with neurogenin 1 enhances the therapeutic potential of mesenchymal stem cells in an amyotrophic lateral sclerosis mouse model," Cell Transplantation, vol. 22, no. 5, pp. 855-870, 2013.
83. J. D. Glass, N. M. Boulis, K. Johe et al., "Lumbar intraspinal injection of neural stem cells in patients with amyotrophic lateral sclerosis: Results of a phase I trial in 12 patients," Stem Cells, vol. 30, no. 6, pp. 1144-1151, 2012.
84. E. L. Feldman, N. M. Boulis, J. Hur et al., "Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis: Phase 1 trialoutcomes," Annals of Neurology, vol. 75,no. 3, pp. 363-373, 2014.